WO2016025882A8 - Médicament à affinité encapsulé dans un liposome - Google Patents

Médicament à affinité encapsulé dans un liposome Download PDF

Info

Publication number
WO2016025882A8
WO2016025882A8 PCT/US2015/045353 US2015045353W WO2016025882A8 WO 2016025882 A8 WO2016025882 A8 WO 2016025882A8 US 2015045353 W US2015045353 W US 2015045353W WO 2016025882 A8 WO2016025882 A8 WO 2016025882A8
Authority
WO
WIPO (PCT)
Prior art keywords
liposome
liposome encapsulated
exterior
affinity drug
interior space
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/045353
Other languages
English (en)
Other versions
WO2016025882A3 (fr
WO2016025882A2 (fr
Inventor
Clet Niyikiza
Jose VARGHESE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEAF Holdings Group LLC
Original Assignee
LEAF Holdings Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AP2017009766A priority Critical patent/AP2017009766A0/en
Priority to AU2015301462A priority patent/AU2015301462B2/en
Priority to EA201790378A priority patent/EA201790378A1/ru
Priority to CA2957775A priority patent/CA2957775C/fr
Priority to MX2017001881A priority patent/MX386433B/es
Priority to EP15832081.2A priority patent/EP3188724B1/fr
Priority to DK15832081.2T priority patent/DK3188724T3/da
Priority to CN201580054566.5A priority patent/CN106794164A/zh
Priority to CN202310777450.0A priority patent/CN117159470A/zh
Priority to BR112017002767-4A priority patent/BR112017002767B1/pt
Priority to JP2017528765A priority patent/JP6825764B2/ja
Application filed by LEAF Holdings Group LLC filed Critical LEAF Holdings Group LLC
Priority to ES15832081T priority patent/ES2905498T3/es
Priority to KR1020177006638A priority patent/KR102505508B1/ko
Publication of WO2016025882A2 publication Critical patent/WO2016025882A2/fr
Publication of WO2016025882A3 publication Critical patent/WO2016025882A3/fr
Anticipated expiration legal-status Critical
Publication of WO2016025882A8 publication Critical patent/WO2016025882A8/fr
Priority to AU2020203241A priority patent/AU2020203241A1/en
Priority to AU2022202046A priority patent/AU2022202046A1/en
Priority to AU2024205501A priority patent/AU2024205501A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

La présente invention concerne une composition liposomale anti-folates comprenant un liposome comportant un espace intérieur, un agent antifolate bioactif situé à l'intérieur dudit espace intérieur, un stabilisant stérique fixé à l'extérieur du liposome, et une fraction de ciblage renfermant une protéine ayant une affinité spécifique pour au moins un récepteur de folate, ladite fraction de ciblage étant fixée au stabilisant stérique et/ou à l'extérieur du liposome.
PCT/US2015/045353 2014-08-14 2015-08-14 Médicament à affinité encapsulé dans un liposome Ceased WO2016025882A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
JP2017528765A JP6825764B2 (ja) 2014-08-14 2015-08-14 リポソームカプセル化親和性薬物
EA201790378A EA201790378A1 (ru) 2014-08-14 2015-08-14 Заключенное в липосому аффинное лекарственное средство
CA2957775A CA2957775C (fr) 2014-08-14 2015-08-14 Medicament a affinite encapsule dans un liposome
MX2017001881A MX386433B (es) 2014-08-14 2015-08-14 Fármaco de afinidad encapsulado en liposoma.
EP15832081.2A EP3188724B1 (fr) 2014-08-14 2015-08-14 Médicament à affinité encapsulé dans un liposome
DK15832081.2T DK3188724T3 (da) 2014-08-14 2015-08-14 Liposom-indkapslet affinitetsmedikament
CN201580054566.5A CN106794164A (zh) 2014-08-14 2015-08-14 脂质体包封的亲和性药物
CN202310777450.0A CN117159470A (zh) 2014-08-14 2015-08-14 脂质体包封的亲和性药物
ES15832081T ES2905498T3 (es) 2014-08-14 2015-08-14 Medicamento con afinidad encapsulado en liposoma
AP2017009766A AP2017009766A0 (en) 2014-08-14 2015-08-14 Liposome encapsulated affinity drug
AU2015301462A AU2015301462B2 (en) 2014-08-14 2015-08-14 Liposome encapsulated affinity drug
BR112017002767-4A BR112017002767B1 (pt) 2014-08-14 2015-08-14 Composição de antifolato lipossomal, seu uso, método de preparação da mesma e kit
KR1020177006638A KR102505508B1 (ko) 2014-08-14 2015-08-14 리포솜 캡슐화 친화 약제
AU2020203241A AU2020203241A1 (en) 2014-08-14 2020-05-19 Liposome encapsulated affinity drug
AU2022202046A AU2022202046A1 (en) 2014-08-14 2022-03-24 Liposome encapsulated affinity drug
AU2024205501A AU2024205501A1 (en) 2014-08-14 2024-08-02 Liposome encapsulated affinity drug

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462037597P 2014-08-14 2014-08-14
US62/037,597 2014-08-14
US201562130493P 2015-03-09 2015-03-09
US62/130,493 2015-03-09
US201562133265P 2015-03-13 2015-03-13
US62/133,265 2015-03-13

Publications (3)

Publication Number Publication Date
WO2016025882A2 WO2016025882A2 (fr) 2016-02-18
WO2016025882A3 WO2016025882A3 (fr) 2016-04-07
WO2016025882A8 true WO2016025882A8 (fr) 2017-03-30

Family

ID=55304769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/045353 Ceased WO2016025882A2 (fr) 2014-08-14 2015-08-14 Médicament à affinité encapsulé dans un liposome

Country Status (15)

Country Link
US (2) US20160228573A1 (fr)
EP (1) EP3188724B1 (fr)
JP (1) JP6825764B2 (fr)
KR (1) KR102505508B1 (fr)
CN (2) CN117159470A (fr)
AP (1) AP2017009766A0 (fr)
AU (4) AU2015301462B2 (fr)
BR (1) BR112017002767B1 (fr)
CA (1) CA2957775C (fr)
DK (1) DK3188724T3 (fr)
EA (1) EA201790378A1 (fr)
ES (1) ES2905498T3 (fr)
MA (1) MA40428A (fr)
MX (1) MX386433B (fr)
WO (1) WO2016025882A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
HK1258650A1 (zh) 2015-09-14 2019-11-15 Vgsk Technologies, Inc. 皮下、舌下和口服治疗用空间稳定载体、用於治疗哺乳动物的组合物和方法
WO2017192863A1 (fr) * 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Compositions de gemcitabine liposomale ciblée et procédés correspondants
WO2018031980A1 (fr) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Antifolates de polyglutamates et leurs utilisations.
WO2018031968A1 (fr) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Antifolates polyglutamés alpha et gamma-d et leurs utilisations
CN121177507A (zh) 2016-08-12 2025-12-23 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
CN106750252B (zh) * 2016-12-05 2018-11-30 山东大学齐鲁医院 二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000-双叶酸及其制备方法和应用
US11311493B2 (en) * 2017-04-07 2022-04-26 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
EP3615005B1 (fr) 2017-04-28 2025-07-30 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Compositions et méthodes d'administration de vaccins
CA3090389A1 (fr) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Raltitrexed alpha-polyglutamate et utilisations associees
WO2019157121A1 (fr) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Lométrexol alpha-polyglutamaté et utilisations associées
JP7491572B2 (ja) * 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
CN111867593A (zh) * 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
US12310966B2 (en) * 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019157129A1 (fr) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Pralatrexate alpha-polyglutamaté et utilisations associées
EP3749318A4 (fr) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Raltitrexed gamma-polyglutamaté et utilisations associées
EP3749321A4 (fr) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Antifolates gamma-polyglutamatés et utilisations associées
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
WO2019157145A1 (fr) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Compositions de pémétrexed polyglutamaté gamma et leurs utilisations
EP3749319A4 (fr) * 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC Tétrahydrofolates alpha polyglutamés et leurs utilisations
EP3749314A4 (fr) * 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC Méthotrexate alpha-polyglutamaté et utilisations associées
WO2019160734A1 (fr) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Lométrexol gamma polyglutamique et ses utilisations
WO2019160735A1 (fr) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Tétrahydrofolates gamma polyglutamiques et leurs utilisations
CA3090753A1 (fr) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Pralatrexate gamma-polyglutamate et utilisations associees
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
JP7462950B2 (ja) * 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
GB201814959D0 (en) * 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
WO2020191305A2 (fr) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Utilisations d'amphiphiles en thérapie cellulaire immunitaire et compositions associées
CN118203546A (zh) * 2019-05-07 2024-06-18 米尼翁大学 生产脂质体的方法
WO2020257260A1 (fr) 2019-06-17 2020-12-24 Massachusetts Institute Of Technology Formulation de liposomes chargés de peptides et applications associées
WO2021150770A1 (fr) * 2020-01-21 2021-07-29 University Of Virginia Patent Foundation Trim37 oncogène est un pilote épigénétique pouvant être ciblé de métastase et lie la chimiorésistance et le devenir métastatique dans le cancer du sein triple-négatif
EP4228660A4 (fr) * 2020-10-14 2025-02-26 Georgia Tech Research Corporation Antigènes synthétiques utiles en tant que ligands récepteurs chimériques de l'antigène (car) et utilisations associées
WO2022235907A1 (fr) 2021-05-05 2022-11-10 Vgsk Technologies, Inc. Inhibition de la réplication du sars-cov-2 et réduction de l'inflammation pulmonaire par corticosteriods encapsulés dans des liposomes
WO2025005632A1 (fr) * 2023-06-26 2025-01-02 주식회사 무진메디 Système d'administration de médicament à base de nanoparticules lipidiques utilisant un peptide ionisable et son procédé de préparation
KR102898792B1 (ko) * 2023-06-26 2025-12-19 주식회사 무진메디 이온화 가능한 펩타이드를 이용한 지질 나노입자 기반 약물 전달체 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
CN101172104B (zh) * 2002-02-22 2013-04-03 默沙东公司 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途
US20100210745A1 (en) * 2002-09-09 2010-08-19 Reactive Surfaces, Ltd. Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
KR101245990B1 (ko) * 2004-03-26 2013-03-20 테루모 가부시키가이샤 리포솜 제제
US20110022529A1 (en) * 2009-07-22 2011-01-27 Fernando Barsoba Social network creation using image recognition
CN102917690B (zh) * 2010-03-19 2016-08-24 麻省理工学院 脂质囊泡组合物和使用方法
CA2800693A1 (fr) * 2010-05-28 2011-12-01 Purdue Research Foundation Apport d'agents therapeutiques a des tissus enflammes au moyen d'agents ciblant le folate
US9549901B2 (en) * 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
WO2012033987A2 (fr) * 2010-09-09 2012-03-15 Purdue Research Foundation Anticorps anti-récepteur bêta de folate humain et leurs procédés d'utilisation
WO2013009701A2 (fr) * 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os
RS61235B1 (sr) * 2011-07-13 2021-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Lipozomi koji ko-inkapsuliraju bisfosfonat i amfipatički agens
US20130122096A1 (en) * 2011-11-14 2013-05-16 Silenseed Ltd. Compositions for drug delivery and methods of manufacturing and using same
WO2013084208A2 (fr) * 2011-12-07 2013-06-13 Universidade Do Minho Liposomes et procédé de production correspondant
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes

Also Published As

Publication number Publication date
MX2017001881A (es) 2017-09-18
US20160228573A1 (en) 2016-08-11
KR20170046145A (ko) 2017-04-28
WO2016025882A3 (fr) 2016-04-07
JP6825764B2 (ja) 2021-02-03
DK3188724T3 (da) 2022-02-07
CN106794164A (zh) 2017-05-31
JP2017526744A (ja) 2017-09-14
AU2022202046A1 (en) 2022-04-14
EP3188724B1 (fr) 2021-11-10
US20250066468A1 (en) 2025-02-27
MA40428A (fr) 2016-02-18
KR102505508B1 (ko) 2023-03-03
BR112017002767A2 (pt) 2017-12-19
MX386433B (es) 2025-03-18
ES2905498T3 (es) 2022-04-08
WO2016025882A2 (fr) 2016-02-18
CA2957775A1 (fr) 2016-02-18
BR112017002767B1 (pt) 2023-09-26
AU2020203241A1 (en) 2020-06-04
EA201790378A1 (ru) 2017-07-31
EP3188724A2 (fr) 2017-07-12
CA2957775C (fr) 2022-10-18
CN117159470A (zh) 2023-12-05
AU2015301462A1 (en) 2017-03-09
AU2015301462B2 (en) 2020-02-27
EP3188724A4 (fr) 2018-01-24
AP2017009766A0 (en) 2017-02-28
AU2024205501A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
WO2016025882A3 (fr) Médicament à affinité encapsulé dans un liposome
EP3578444A4 (fr) Structure inférieure de carrosserie de véhicule pour véhicule
ZA201902562B (en) Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
CA2956871C (fr) Composes actifs envers des bromodomaines
USD806481S1 (en) Combined dish and cup
EP3129065A4 (fr) Administration ciblée d'un médicament faisant appel à des coupleurs fondés sur l'affinité
EP3265063A4 (fr) Formulations pharmaceutiques liposomales à double charge
AU2016289474B2 (en) HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
IL291628B1 (en) A liposomal preparation for drug administration
EP3395655A4 (fr) Structure de carrosserie de véhicule
SG11202002422WA (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
WO2016130581A8 (fr) Polythérapie anticancéreuse
HUE047144T2 (hu) 7-(morfolinil)-2-(N-piperazinil) metil-tieno-[2,3-C]piridin-származékok mint rákellenes gyógyszerek
SI4056557T1 (sl) Derivati benzazepina uporabni kot zdravila
WO2015100370A3 (fr) Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes
EP3787935A4 (fr) Structure de carrosserie de véhicule
EP3655106A4 (fr) Polythérapie
EP3572306A4 (fr) Structure avant de carrosserie de véhicule
EP3643497A4 (fr) Corps composite
IL274868A (en) History of imidazopyridine and their use as medicine
EP3663279A4 (fr) Dérivé d'adamantylméthylamine et son utilisation en tant que produit pharmaceutique
EP3560984A4 (fr) Corps structural
EP3143017A4 (fr) Dérivés bicycliques et composition pharmaceutique les contenant
HK40007666A (en) Antibody drug conjugates having derivatives of amatoxin as the drug
HK40037206A (en) Stabilized peptide-mediated targeted protein degradation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15832081

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2957775

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017528765

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/001881

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015832081

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015832081

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017002767

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20177006638

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2015301462

Country of ref document: AU

Date of ref document: 20150814

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201790378

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15832081

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112017002767

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170210